Autism Research Leaders Launch Independent Committee to Counter RFK’s Panel

Why It Matters

The independent committee safeguards the integrity of U.S. autism research funding and ensures that policy remains grounded in rigorous science, protecting patients and taxpayers from fringe theories.

Key Takeaways

• Independent committee formed to safeguard evidence‑based autism research
• Federal IACC oversees roughly $2 billion annual autism funding
• Appointees include individuals linked to anti‑vaccine positions
• I‑ACC will meet same day as federal IACC, March 19
• Goal: publicly clarify misinformation affecting public‑health decisions

Pulse Analysis

The Interagency Autism Coordinating Committee (IACC) has long served as the linchpin for coordinating federal autism research, aligning roughly $2 billion in annual funding across agencies. Established in 2006, the panel brings together clinicians, scientists, advocates, and self‑advocates to set research agendas that span genetics, neurobiology, and service delivery. Recent appointments by HHS Secretary Robert F. Kennedy Jr. introduced members with ties to anti‑vaccine rhetoric, sparking concern among mainstream researchers that the advisory body could drift toward discredited theories and dilute evidence‑based priorities.

In response, a coalition of top autism scientists and advocacy leaders created the Independent Autism Coordinating Committee (I‑ACC). The new group mirrors the federal schedule, convening its inaugural session on March 19, 2026, the same day the IACC meets. By assembling experts committed to rigorous methodology, the I‑ACC aims to draft a strategic research agenda that foregrounds genetic, neurological, and environmental studies while explicitly countering misinformation that could sway public‑health policy.

The emergence of the I‑ACC reflects a broader tension in U.S. health governance, where independent panels are forming to offset perceived politicization of federal advisory committees. For stakeholders—research institutions, pharmaceutical firms, families, and policymakers—the parallel structure offers a transparent benchmark of scientific consensus. If successful, the I‑ACC could influence future federal appointments, reinforce the credibility of autism research funding, and serve as a model for safeguarding evidence‑based decision‑making across other public‑health domains.